Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XY0206 QTc study in healthy volunteers
NCT07162116Phase 1Recruiting
- Sponsor
- Yiling Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XY0206 in acute myeloid leukemia (AML), sponsored by Yiling Pharmaceutical. Primary endpoint: QT/QTc Interval at 48 hours. Started Jul 2025; status: recruiting.
02
Drugs
XY0206
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07162116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162116.